Received 26 February 1997/Returned for modification 16 September 1997/Accepted 10 February 1998
|
|
- Alan Butler
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p Vol. 42, No /98/$ Copyright 1998, American Society for Microbiology Comparison of Concentrations of -Ampicillin Administered by Bolus Injections or Bolus plus Continuous Infusion in Tissues of Patients Undergoing Colorectal Surgery CLAUDE MARTIN, 1 * AGNÈS COTIN, 2 ANNICK GIRAUD, 1 MIREILLE BECCANI-ARGÈME, 1 PIERRE ALLIOT, 3 MARIE-NOËLLE MALLET, 2 AND MAXIME ARGÈME 3 Department of Anesthesia and Intensive Care, Nord Hospital, Marseilles University Hospital System and Marseilles Medical School, 1 Microbiology Department, Salvator Hospital, 2 and Surgical Departement, Nord Hospital, 3 Marseilles, France Received 26 February 1997/Returned for modification 16 September 1997/Accepted 10 February 1998 The concentrations of sulbactam and ampicillin were determined in sera and different abdominal tissues of 16 patients who underwent elective colorectal surgery. Patients were randomly allocated to two groups. At the time of induction of anesthesia, patients in group 1 (eight patients) were given 1,000 mg of sulbactam with 2,000 mg of ampicillin by intravenous bolus injection (3 min). This dose was administered again after 2 h by bolus injection by the same route. Patients in group 2 (eight patients) were given the same initial dose of sulbactamampicillin by bolus injection (3 min). Then, a continuous infusion of 1,000 mg of sulbactam with 2,000 mg of ampicillin in normal saline was immediately started and was administered over a 4-h period. Blood samples were collected to determine peak (10 min) and trough (end of surgery) antibiotic levels. Serial blood samples were also collected at predetermined periods (at the time of opening and closing of the abdominal cavity and at the time of surgical anastomosis). wall fat, epiploic fat, and colonic wall tissue samples were collected simultaneously. Antibiotic concentrations were determined by high-performance liquid chromatography. Similar levels of the drugs in serum were observed for the two regimens of administration, with trough sulbactam levels of and g/ml in groups 1 and 2, respectively, and trough ampicillin levels of and g/ml in groups 1 and 2, respectively. Similar sulbactam concentrations were observed in abdominal tissues whichever regimen of administration was used; in fatty tissues the sulbactam concentrations ranged from 2.7 to 3.8 g/g for group 1 and from 1.7 to 4.0 g/g for group 2, and sulbactam concentrations in the colonic wall were and g/g in groups 1 and 2, respectively (not significant). Again, no influence of the regimen of administration was observed on tissue ampicillin concentrations; in fatty tissues ampicillin concentrations ranged from 4.1 to 5.4 g/g for group 1 and from 3.2 to 5.8 g/g for group 2, and sulbactam concentrations in the colonic wall were and g/g for groups 1 and 2, respectively (not significant). In most patients, the concentrations of ampicillin-sulbactam were greater than the MIC at which 50% of isolates are inhibited (MIC 50 ) for Bacteroides fragilis in the fatty tissues. In the colonic wall, for most patients the concentrations of ampicillin-sulbactam were greater than the MIC 90 for B. fragilis. No influence of the regimen of administration was observed on the ratio of the two components in the tissues investigated and in sera. In conclusion, a second intraoperative bolus injection or a continuous infusion were equally effective in maintaining sulbactam-ampicillin concentrations in abdominal tissues. The first method of administration can be recommended since it is easier to handle. Colorectal surgery is a contaminated aseptic type of surgery, and prophylactic antibiotics are widely used prior to and during surgery. The importance of the prophylactic antibiotics in reducing postoperative infections and mortality has been demonstrated (4, 15, 22). Antibiotics are selected on the basis of their ability to eradicate the bacteria most likely to contaminate a surgical wound: Escherichia coli and various members of the family Enterobacteriaceae, Enterococcus faecalis, Staphylococcus aureus, Bacteroides fragilis, and other anaerobic bacteria (4, 15, 22). The basic concept underlying the optimal use of antibiotic prophylaxis is that an adequate amount of an appropriate antibiotic should be present in the blood and tissues before a bacterial challenge. It seems clear that during a surgical procedure, adequate antibiotic concentrations should be achieved at all sites of potential infection. Also, antibiotic activity should be maintained throughout the procedure, from * Corresponding author. Mailing address: Département d Anesthésie, Hôpital Nord, Marseille Cedex 20, France. Phone: Fax: cmartin@ap-hm.fr. incision to closure (7, 9, 18, 19). The combination of sulbactam-ampicillin can be selected for use as a prophylactic antibiotic in abdominal surgery (10, 11, 23). It is effective in the prevention of wound infections in operations in which the most likely pathogens are gram-negative, anaerobic, or mixed bacteria (20). However, sulbactam-ampicillin has a short half-life (1 h) (8, 12), and for longer procedures such as colorectal surgery, antibiotic concentrations may not be maintained until the end of surgery when the first bolus dose is administered at the time of induction of anesthesia (7, 18, 19). When intermittent antibiotic dosing is used, antibiotic levels in serum and tissues will gradually decrease and the bacteria will often be exposed to low concentrations during the dosing interval. The present study was conducted during colorectal surgery to compare the antibiotic activities of two different regimens of intraoperative antibiotic administration: the use of a second bolus injection 2 h after the beginning of surgery or the use of a continuous antibiotic infusion during surgery. We wanted to confirm the maintenance of antibacterial concentrations of the antibiotics at potential sites of infection. 1093
2 1094 MARTIN ET AL. ANTIMICROB. AGENTS CHEMOTHER. Concn TABLE 1. Concentrations of sulbactam and ampicillin in serum a Group 1 Group 2 Ampicillin concn/ampicillin concn ratio Ampicillin concn/ampicillin concn ratio Peak (10 min) Trough (end of surgery) b a Values are means standard deviations. b Group 1, min; group 2, min. MATERIALS AND METHODS Patients and drugs. This study received the approval of the ethical committee of our institution (Hopital Nord), and all patients gave their informed consent. Fifteen patients were scheduled for elective colorectal surgery. All patients had normal hepatic function (serum bilirubin level, 10 mol/liter) and renal function (creatinine clearance, 100 ml/min/1.74 m 2 ). None had a history of allergic reaction to -lactam antibiotics. None presented with any clinical sign (normal body temperature, normal physical examination) or laboratory sign (normal leukocyte count) of infection or had received antibiotic treatment in the preceding 3 weeks. Patients were randomly assigned to one of two groups. Patients in group 1 (five males and three females; mean age, years; mean body weight, kg) were given 1,000 mg of sulbactam with 2,000 mg of ampicillin by intravenous bolus injection (3 min). This dose was administered again after 2 h. Patients in group 2 (six males and two females; mean age, years; mean body weight, kg) were given by intravenous bolus injection (3 min) the same initial dose of sulbactam-ampicillin used for group 1 patients, and a continuous infusion of 1,000 mg of sulbactam with 2,000 mg of ampicillin in normal saline was immediately started and administered over a 4-h period. Specimen collection. Blood samples (10 ml each) were collected from a central venous catheter before surgery, 10 min after the beginning of surgery (peak level), and at the end of surgery (trough level). Blood samples were kept on ice and were centrifuged in a refrigerated centrifuge within 30 min of collection. Sera were placed in polypropylene tubes. Several samples of the selected tissues were collected during surgery. wall fat and epiploic fat were obtained at the times of opening and closure of the abdominal cavity; colonic wall and epiploic fat samples were obtained at the time of surgical anastomosis. The exact time of sample collection was registered, and a corresponding blood sample was taken. Tissue sample sizes were 1 cm 3 or larger. To remove the attached blood, all tissue samples were rinsed in sterile saline and were cleaned with dry, sterile gauze. Tissue samples were placed in sterile polypropylene tubes. and tissue samples were assayed immediately following surgery. Specimen preparation procedures. For determination of sulbactam levels in serum, 1 ml of the sample was mixed with 0.5 ml of imidazole (2.5 M; ph 6.8) (5, 21). The solution was stored for 24 h at 4 C. After mixing (with a Vortex mixer for 30 s) the sample was deproteinized by the addition of 2.0 ml of acetonitrile. After mixing (15 s) and centrifugation at 3,000 rpm (Sorvall centrifuge) for 10 min, acetonitrile was removed by extraction with 3.0 ml of dichloromethane. Then, the solution was vortexed (30 s) and centrifuged at 3,000 rpm (Sorvall centrifuge) for 5 min. The aqueous phase (50 l) was injected onto the highperformance liquid chromatography (HPLC) system. For determination of ampicillin levels in serum, 1 ml of the sample was mixed with 1 ml of acetonitrile. After mixing and centrifugation the sample was then treated in the same way that the sulbactam samples were. The aqueous phase (50 l) was injected onto the HPLC system. For determination of the sulbactam and ampicillin levels in the tissues, the samples were weighed and 500 mg was homogenized with an Ultra-Turrax homogenizer at 4.0 C for 45 s. One milliliter of distilled water was used for the tissue homogenization process. Centrifugation of the homogenate yielded a clear supernatant which was treated like serum samples were. HPLC systems. The sulbactam concentrations were determined by using a dual-column HPLC system with UV detection (5, 21). The precolumn (LiChrospher RP 18 E, 5 mm; 25 by 4 mm [inner diameter]) was connected to the analytical column (LiChrospher RP 18 E, 5 m; 125 by 4 mm [inner diameter]). The mobile phase consisted of 2% acetonitrile and 98% 0.1 M potassium phosphate buffer (ph 6.1). The flow rate was 1.0 ml/min, and sulbactam was detected at 322 nm. The ampicillin concentrations were determined by using the same HPLC systems described above. The mobile phase consisted of 5% acetonitrile and 95% 0.01 M potassium phosphate buffer (ph 4.7). The flow rate was 1.6 ml/min, and ampicillin was detected at 219 nm. The lower limit of detection of sulbactam and ampicillin was 0.1 g/ml for tissue and serum samples. The percent recoveries for sulbactam were 89% 4% and 91% 3% for serum and tissue samples, respectively. The percent recoveries for ampicillin were 94% 2% and 93% 4% for serum and tissue samples, respectively. For sulbactam, the within-day and between-day (3 days) interassay precisions were 1.43 and 1.41% (20 g/ml) and 2.79 and 2.77% (40 g/ml) for serum samples, respectively, and 3.3 and 5.0% (3 g/g) and 4.2 and 6.4% (0.5 g/g) for tissue samples, respectively. For ampicillin the within-day and between-day (3 days) interassay precisions were 1.46 and 1.20% (25 g/ml) and 1.77 and 1.24% (50 g/ml) for serum samples, respectively, and 3.7 and 5.2% (15 g/g) and 5.3 and 6.7% (1 g/g) for tissue samples, respectively. Evaluation of sulbactam:ampicillin ratios. Samples of specific tissues were analyzed according to collection time: opening and closure of the abdominal cavity and surgical anastomosis of the colon. For each defined period, the ratios of the concentrations of the two compounds (sulbactam and ampicillin) were obtained for the different tissue samples and the corresponding serum samples. The mean the standard deviation ratio was calculated for both groups. Antibiotic concentrations in tissues were also compared to the MICs at which 50% (MIC 50 s) and 90% (MIC 90 s) of Bacteroides fragilis isolates are inhibited (2 and 8 mg/liter for sulbactam and ampicillin, respectively), assuming a 1:2 sulbactamto-ampicillin ratio. Clinical evaluation. All patients were closely monitored during their hospital stays and for up to 30 days for clinical or laboratory signs of infection. Statistical analysis. Statistical analysis was performed by Student s t test for unpaired values and the chi-square test. A P value of less than 0.05 was considered significant. RESULTS Concentrations in serum. The sulbactam and ampicillin concentrations in serum are presented in Table 1. No significant differences in concentrations in serum were observed, whichever drug regimen used. At the end of surgery both methods of drug administration achieved high levels of sulbactam and ampicillin in the two groups. Antibiotic concentrations in tissues. The sulbactam and ampicillin concentrations in tissues at various periods during surgery are presented in Table 2. Stable concentrations of antibiotics were observed in fatty tissues when the concentrations at the surgical opening and closure periods are compared. This was observed after administration of a second bolus dose or the use of the continuous infusion during surgery. No significant differences were observed between the two groups. and ampicillin concentrations were higher in the colonic wall than in fatty tissues. The mode of antibiotic administration during surgery had no influence on the concentrations achieved in colonic wall samples. -to-ampicillin concentration ratios. The sulbactam-to-ampicillin concentration ratios are presented in Tables 1 and 3. For group 1, they ranged from 0.33 to 0.70 in tissues and from 0.44 to 0.67 in serum. For group 2, the ratios ranged from 0.41 to 0.69 in tissues and from 0.46 to 0.67 in serum. The ratios were not significantly modified by the method of administration of antibiotics during surgery. Table 4 presents data for the patients who achieved ampicillin-sulbactam concentrations in tissue greater than the MIC for B. fragilis. For most patients concentrations in the fatty tissues greater than the MIC 50 were achieved, but only in the colonic wall were concentrations greater than the MIC 90 for B. fragilis achieved. No patient had any signs of postoperative infection during the 30-day follow-up period.
3 VOL. 42, 1998 COMPARISON OF CONCENTRATIONS BY ADMINISTRATION REGIMEN 1095 TABLE 2. Concentrations of sulbactam and ampicillin in abdominal tissues and serum of patients undergoing colorectal surgery at different periods of the surgical procedure Mean SD drug concn at the following times: Group and drug a wall Opening b Surgical anastomosis c Closure d Colonic wall ( g/g) wall Group 1 d e Ampicillin e Group 2 d e Ampicillin e a Bolus and infusion doses were 1,000 mg for sulbactam and 2,000 mg for ampicillin. b For groups 1 and 2, the opening times in relation to the start of antibiotic administration were 35 6 and 36 7 min, respectively. c For groups 1 and 2, the surgical anastomosis times in relation to the start of antibiotic administration were and min, respectively. d For groups 1 and 2, the closure times in relation to the start of antibiotic administration were and min, respectively. e P 0.02 compared with concentrations in fatty tissues. DISCUSSION This study shows that the intraoperative administration of sulbactam-ampicillin as two sequential bolus injections or by bolus injection plus a continuous infusion during surgery had no significant influence on antibiotic penetration into tissue. Previous studies have established the basic principles of antibiotic prophylaxis in surgical procedures, and the main points are that (i) the antibiotic must reach the tissues involved before surgery allows bacterial contamination, and (ii) the drug must attain and maintain concentrations in serum and tissues high enough to inhibit the growth of contaminating pathogens (7, 9, 15, 22). This study addressed the tissue penetration of a -lactam -lactamase inhibitor combination, with the drugs being administered as two sequential bolus injections or one bolus injection immediately followed by a continuous infusion during the intraoperative period. The absolute concentrations of the drugs in tissues, the time course of these concentrations, and the extent of penetration are of interest. Penetration was evaluated by measuring the concentration in tissue-to-concentration in plasma ratios at specific collection times. The data for sulbactam and ampicillin are in agreement with results reported previously (11, 13, 14). Specific differences between tissues were observed. The extent of sulbactam and ampicillin penetration into fat was 4 to 8% of the levels in serum, significantly lower than the penetration into the colonic wall (10 to 20%; P 0.02). This is in agreement with a study on the penetration of tazobactam-piperacillin into fat, which was 10% of the levels in plasma (16), but is at variance with a study with clavulanic acid-amoxicillin, in which the former drug had a higher level of penetration (30%) than the latter drug (10 to 20%) (17). The exact mechanisms that cause these important findings deserve further investigations. The level of penetration of sulbactam and ampicillin into the colonic wall was higher than that into fatty tissues. This might be explained by the fact that the blood flow to the gastrointestinal tract is higher than that to the fat. From these data, it is clear that no single mechanism governs the extent of penetration of antibiotics into tissues. Further investigations are needed to more clearly define the relationship among blood flow, water content, and the physicochemical properties of the agents. In the present study, the extent of penetration of both compounds (sulbactam and ampicillin) was maintained throughout the surgical procedure thanks to the intraoperative administration of the antibiotics. In clinical practice, when intermittent antibiotic dosing is used, antibiotic levels in serum and tissues will gradually decrease. The bacteria will often be exposed to low concentrations of the antibiotic during the dosing interval and infection may start in the tissues potentially affected by postoperative infection. This emphasizes the need for repeated administration of drugs with shorter half lives (7, 15, 17, 22), such as sulbactam and ampicillin (8, 12). If the intraoperative administration is not performed, decreased concentrations of both compounds, sulbactam and ampicillin, would probably be measured in fatty tissues and colonic wall, with an increased risk of postoperative infection. To maintain active concentrations of antibiotics, one can consider either the administration of a second intraoperative bolus injection or continuous administration during surgery. The administration of an intraoperative bolus dose (after 2 h, which corresponds to two halflives for most antibiotics used) is recommended, but objective data are lacking (7, 15, 22). -Lactam antibiotics can also be administered by continuous infusion (6), and in the present TABLE 3. concentration/ampicillin concentration ratios at different periods of the surgical procedure in patients undergoing colorectal surgery Group a wall fat Mean SD sulbactam concn/ampicillin concentration ratio at the following times: Opening Surgical anastomosis Closure fat Colonic wall fat wall fat fat Group Group a Bolus and infusion doses were 1,000 mg for sulbactam and 2,000 mg for ampicillin.
4 1096 MARTIN ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 4. Numbers of patients with concentrations in tissue greater than or equal to the MIC 50 and MIC 90 for B. fragilis at the different periods of the surgical procedure No. of patients with the indicated concn/total no. of patients Group Opening Surgical anastomosis Closure wall fat fat Colonic wall fat wall fat fat MIC 50 MIC 90 MIC 50 MIC 90 MIC 50 MIC 90 MIC 50 MIC 90 MIC 50 MIC 90 MIC 50 MIC 90 Group 1 8/8 1/8 8/8 1/8 8/8 5/8 8/8 1/8 7/8 1/8 8/8 0/8 Group 2 8/8 1/8 8/8 1/8 8/8 7/8 7/8 1/8 7/8 1/8 6/8 0/8 study, both routes of administration were compared. With either route, the same concentrations in serum (including trough levels), the same antibiotic concentrations in tissues, the same concentration in tissue/concentration in serum ratios, and the same sulbactam-to-ampicillin concentration ratios were achieved. Thus, both administration regimens were equally effective at preventing fluctuating antibiotic concentrations during colorectal surgery. Since the administration of a second intraoperative dose is easier to handle than a continuous infusion, the former route of administration can be selected for clinical use. Current practice with -lactam -lactamase inhibitor combinations is to maintain an optimal ratio between the two components (1:2 sulbactam to ampicillin) (3). Because of their similar pharmacokinetics these two components theoretically maintain a 1:2 ratio at the site of potential infection over the entire period of surgery. In the present study, ratios close to 1:2 were obtained in the tissues studied, but it has been suggested that the efficacy of sulbactam-ampicillin is more dependent upon the maintenance of both sulbactam and ampicillin levels above a minimum critical concentration than on the maintenance of a constant 1:2 ratio (2). With both regimens of antibiotic administration used in the present study, the levels of sulbactam and ampicillin were maintained in the studied tissues until the end of surgery. Will these concentrations be active against the most common pathogens encountered during surgery? It can be speculated that a desirable goal is to achieve antibiotic levels above the MIC for the potential pathogen. This also means maintaining such levels until the end of the surgical procedure (7, 19). At the time of closure of the abdomen, sulbactam concentrations in the fatty tissues reached an average of 2 g/g. At this concentration of sulbactam, the ampicillin MIC for plasmid-mediated -lactamaseproducing strains of E. coli can be as high as 16 g/ml (1). Given the average level of ampicillin achieved in the same tissues (Table 2), some patients can be at risk of postoperative infection. This finding was observed whatever the regimen of antibiotic administration used. With regard to B. fragilis, in most patients, antibiotic levels greater than the MIC 50 were achieved in the fatty tissues up to the end of surgery, but only in the colonic wall were antibiotic concentrations greater than the MIC 90 for this organism achieved. From a clinical point of view, in the present study no patient exhibited any clinical or laboratory signs of postoperative infection during the 30-day follow-up period. In conclusion, the results of this study indicate that the intraoperative administration of sulbactam-ampicillin is able to maintain constant antibiotic levels in tissue during surgery. After the administration of a first bolus injection 30 min prior to surgery, antibiotic levels can be maintained either by the injection of a second bolus dose after 2 h (two half-lives) or by the use of a continuous infusion started immediately after administration of the first bolus dose and administered over 4h. REFERENCES 1. Aldridge, K. E., D. Ashcraft, and K. A. Bowman Comparative in vitro activities of trovafloxacin (CP 99, 219) and other antimicrobials against clinically significant anaerobes. Antimicrob. Agents Chemother. 41: Alexov, M., P. D. Lister, and C. C. Sanders Efficacy of ampicillinsulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Antimicrob. Agents Chemother. 40: Appelbaum, P. C., M. R. Jacobs, S. K. Spangler, and S. Yamabe Comparative activity of -lactamase inhibitors YTR 30, clavulanate, and sulbactam combined with -lactams against -lactamase-producing anaerobes. Antimicrob. Agents Chemother. 30: Baum, M. L., D. S. Anisch, T. C. Chalmers, M. S. Sacks, H. Smith, and R. M. Fagerstrom A survey of clinical trials of antibiotic prophylaxis in colon surgery. Evidence against further use of no treatment controls. N. Engl. J. Med. 305: Bawdon, R. E., and P. O. Madsen High-pressure liquid chromatography assay of sulbactam in plasma, urine, and tissues. Antimicrob. Agents Chemother. 30: Benko, A. S., D. M. Cappelletty, J. A. Kruse, and M. J. Rybak Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob. Agents Chemother. 40: Bergamini, T. M., and M. C. Polk The importance of tissue antibiotic activity in the prevention of operative wound infection. J. Antimicrob. Chemother. 23: Brown, R. M., R. Wise, J. M. Andrews, and J. Hancox Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob. Agents Chemother. 21: Burke, J. F The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 50: De la Hunt, H. N., S. J. Karran, and M. Chir /ampicillin compared with cefoxitin for chemoprophylaxis in elective colorectal surgery. Dis. Colon Rectum 29: Foster, M. C., L. Kapila, D. L. Morris, and R. C. B. Slack A randomized comparative study of sulbactam plus ampicillin VS metronidazole plus cefotaxime in the management of acute appendicitis in children. Rev. Infect. Dis. 8(Suppl. 5): Foulds, G., J. P. Stankewich, D. C. Marshall, M. M. O Brien, and S. L. Hayes Pharmacokinetics of sulbactam in humans. Antimicrob. Agents Chemother. 23: Houang, E., N. Colley, and M. Chapman Penetration of sulbactamampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum. Antimicrob. Agents Chemother. 28: Kager, L., A. S. Malmborg, S. Sjöstedt, and C. E. Nord Concentrations of ampicillin plus sulbactam in serum and intestinal mucosa and effects on the colonic microflora in patients undergoing colorectal surgery. Eur. J. Clin. Microbiol. 2: Kaiser, A. B Antimicrobial prophylaxis in surgery. N. Engl. J. Med. 315: Kinzig, M., F. Sörgel, B. Brismar, and C. E. Nord Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36: Martin, C., M. N. Mallet, B. Sastre, X. Viviand, A. Martin, P. De Micco, and F. Gouin Comparison of concentrations of two doses of clavulanic acid (200 and 400 milligrams) administered with amoxicillin (2,000 milligrams) in tissues of patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 39: Martin, C., C. Portet, D. Lambert, B. Bruguerolle, B. Sastre, P. De Micco,
5 VOL. 42, 1998 COMPARISON OF CONCENTRATIONS BY ADMINISTRATION REGIMEN 1097 and F. Gouin Pharmacokinetics and tissue penetration of single dose cefotetan used for antimicrobial prophylaxis in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36: Martin, C., B. Sastre, M. N. Mallet, B. Bruguerolle, J. P. Brun, and F. Gouin Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob. Agents Chemother. 35: Medeiros, A. A Lactamases. Br. Med. Bul. 40: Rogers, H. J., I. D. Bradbrook, P. J. Morisson, R. G. Spector, D. A. Cox, and I. J. Lees Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography. J. Antimicrob. Chemother. 11: Stone, H. H Basic principles in the use of prophylactic antibiotics. J. Antimicrob. Chemother. 14(Suppl. B): Wildfeuer, A., U. Schwiersch, K. Engel, E. Castell, A. Schilling, J. Potempa, and H. Lenders Pharmacokinetics of sulbactam and ampicillin intravenously applied in combination to healthy volunteers and patients. Arzneim.-Forsch./Drug. Res. 38(Suppl. 2):
Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro Infection Model against Escherichia coli Strains with Various Levels of Resistance
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1998, p. 231 235 Vol. 42, No. 2 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro
More informationHysterectomy. Penetration of Piperacillin/Tazobactam Into Gynecologic Tissues Following a Single Loading Dose Prior to
Infectious Diseases in Obstetrics and Gynecology 2:20-24 (1994) (C) 1994 Wiley-Liss, Inc. Penetration of Piperacillin/Tazobactam Into Gynecologic Tissues Following a Single Loading Dose Prior to Hysterectomy
More informationOptimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer
Tomizawa et al. Journal of Pharmaceutical Health Care and Sciences (2017) 3:1 DOI 10.1186/s40780-016-0071-6 RESEARCH ARTICLE Open Access Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis
More informationPharmacokinetics as applied to in vitro and animal models
Pharmacokinetics as applied to in vitro and animal models Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics In vitro pharmacodynamic models
More informationPolymicrobial Infection in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P. 1531-1535 0066-4804/93/071531-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 7 Use of Cephalosporins for Prophylaxis and
More information4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF. The microbiological assay was performed by using the test
109 4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF AMOXICILLIN The microbiological assay was performed by using the test organism Staphylococcus aureus. The strain was isolated from soil and allowed
More informationDissociation of Pharmacokinetic-Pharmacodynamic Success and Clinical Failure of Tazobactam/Piperacillin in Escherichia coli Bacteremia: A Case Report
Elmer Press Case Report Dissociation of Pharmacokinetic-Pharmacodynamic Success and Clinical Failure of Tazobactam/Piperacillin in Escherichia coli Bacteremia: A Case Report Hiroki Magarifuchi a, b, c,
More informationAre There Non-Carbapenem β-lactam Options for Treating ESBL Infections?
CIDEIM Are There Non-Carbapenem β-lactam Options for Treating ESBL Infections? Pranita D. Tamma, M.D., M.H.S. Assistant Professor, Pediatrics Director, Pediatric Antimicrobial Stewardship Program CIDEIM
More informationSetting Clinical Breakpoints/ECOFFS
23 rd August 2016 Setting Clinical Breakpoints/ECOFFS Robin A Howe Antimicrobial use in Primary Care An E. coli is grown from blood cultures Cefuroxime MIC 2mg/L Zone around CXM 30ug disc 27mm Is it sensitive?
More informationNovel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program
Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program An industry view John H. Rex, Infection Clinical Vice President AstraZeneca Pharmaceuticals
More informationJohan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands
Can pk/pd replace clinical trials? Johan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands The Traditional Approach Phase Participants Research questions Number Characteristics I 10-50 Usually
More informationInvestigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing
Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Erika Matuschek, Ph D Lead Scientist/Operational Manager EUCAST Development Laboratory (EDL) Växjö, Sweden ASM/ESCMID
More informationKazuro Ikawa, PhD 1 Norifumi Morikawa, PhD 1 Kayo Ikeda, PhD 1 Mitsuru Sakashita, MD 2 Hiroki Ohge, MD 2 Taijiro Sueda, MD 2
Penetrability of Intravenous Biapenem Into the Peritoneal Fluid of Laparotomy Patients and the Peritoneal Pharmacodynamics Against Gram-negative Bacteria Kazuro Ikawa, PhD 1 Norifumi Morikawa, PhD 1 Kayo
More informationThe Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions.
The Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions. Philippe Lagacé-Wiens, MD FRCPC, DTM&H plagacewiens@sharedhealthmb.ca COI declaration I have no conflicts, real
More informationIDSA is pleased to offer the following comments on specific priority areas identified by FDA:
October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 27 July 2000 CPMP/EWP/2655/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER
More informationPharmacology of Amikacin in Humans
ANTIMICROBILm AGNTS AND CHMOTHRAPY, May 1974, p. 8-12 Copyright 1974 American Society for Microbiology Vol., No. Printed in U.S.A. Pharmacology of Amikacin in Humans GRALD P. BODY, MANUL VALDIVISO, RONALD
More informationBeta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of betalactamase inhibiter combinations
Beta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of betalactamase inhibiter combinations Dr Shampa Das, Senior Lecturer, Molecular and Clinical Pharmacology,
More informationEffect of Diuresis on Staphylococcus aureus Kidney
INFECTION AND IMMUNITY, Dec. 1971, p. 74-746 Copyright 1971 American Society for Microbiology Vol. 4, No. 6 Printed in U.S.A. Effect of Diuresis on Staphylococcus aureus Kidney Infections in Mice DOLORES
More informationNovel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program
Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program An industry view John H. Rex, Infection Clinical Vice President AstraZeneca Pharmaceuticals
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #21 (NQF 0268): Perioperative Care: Selection of Prophylactic Antibiotic First OR Second Generation Cephalosporin National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL
More information2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research. Pharmacological Approaches to Address AR
2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research Pharmacological Approaches to Address AR G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation
More information3.0. Materials and methods
63 3.0. Materials and methods 3.1. Plant materials and preparation of extracts Salacia oblonga plants were collected from Western Ghats, Karnataka, India. S. oblonga (RRCBI 7881) authentication was done
More informationMicrobiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration
Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration John W. Metcalfe, Ph.D. Senior Review Microbiologist FDA/CDER/OPS/New
More informationDivision of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
May 24, 2012 Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: Comments on Docket #FDA- 2012 D 0148; Draft Guidance for Industry
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More informationAmpicillin and Sulbactam Pharmacokinetics and Pharmacodynamics in Continuous Ambulatory Peritoneal Dialysis (CAPD)
Peritoneal Dialysis International, Vol. 10, pp. 221-226, 1990 0896-8608/90 $300 + 00 Printed in the USA All rights reserved Copyright 1990 Peritoneal Dialysis Bulletin, Inc Ampicillin and Sulbactam Pharmacokinetics
More informationA clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction?
A clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction? Author: apr. Bart Peeters Supervisor: dr. Reinoud Cartuyvels Date: 19/05/2015 Content
More informationClinical Pharmacology of Ceftriaxone in Patients with
ANTIMICROBIAL AOENTS AND CHEMorHERAPY, Apr. 1983, p. 583-588 0066-4804/83/040583-06S02.00/0 Copyright C 1983, American Society for Microbiology Vol. 23, No. 4 Clinical Pharmacology of Ceftriaxone in Patients
More informationRapid Analysis of Cefazolin in Serum by High-Pressure
ANTMCROBIAL AGzNTS ANm CHEMOTHERAY, Jan. 1977, p. 105-109 Copyright X) 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. Rapid Analysis of Cefazolin in Serum by High-Pressure Liquid
More informationABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18
M26-A ISBN 1-56238-384-1 September 1999 ISSN 0273-3099 Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline Volume 19 Number 18 Arthur L. Barry, Ph.D. William A. Craig,
More information6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationRecommended Agent First alternative for β-lactam allergy Alternative Agents (in order of preference) document β-lactam allergy for SCIP)
Surgical Prophylaxis Guideline Updates Wadley Regional Medical Center Surgery and Trauma Committee, July 22, 2014 Pharmacy and Therapeutics Committee, August 2014 Compiled by: Andrea C Jarzyniecki, Pharm
More informationDaptomycin: a new-old antibiotic or how did pharmacodynamics bring back to life a disappointing drug?
Daptomycin: a new-old antibiotic or how did pharmacodynamics bring back to life a disappointing drug? Unité de Pharmacologie cellulaire et moléculaire F. Van Bambeke Origin of daptomycin Daptomycin is
More informationDirect anticoagulation therapy
Direct anticoagulation therapy Pan-Arab Meeting & Saudi Society of Hematology Dr Ihab Alhemaidi MBBS MRCP(Lond UK) FRCPath. Fellow of the Royal Society of Medicine Consultant Adult hematology/bmt Section
More informationReceived 9 September 1996/Returned for modification 7 November 1996/Accepted 24 December 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1997, p. 630 635 Vol. 41, No. 3 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Bactericidal Activity of Low-Dose Clindamycin Administered
More informationBiofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement
Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms
More information10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationAntibiotic prophylaxis in surgery (ADULTS) Type of Surgery Antibiotic of Choice Alternative in true Penicillin Allergy or MRSA carriage
These guidelines have been amended to reduce the incidence of Clostridium difficile associated diarrhoea and includes recommendations from the most recent guidance 1-8 NB. If patient is a VRE carrier or
More informationGENOMERA TM MRSA/SA PRODUCTS A NEW ERA IN DIRECT MRSA DNA TESTING. Bringing genetic MRSA results in less than 1 hour!
GENOMERA TM MRSA/SA PRODUCTS A NEW ERA IN DIRECT MRSA DNA TESTING Bringing genetic MRSA results in less than 1 hour! IMPROVING PATIENT CARE THROUGH EARLIER DETECTION OF MRSA AND SA FAST MRSA AND SA DETECTION
More informationEliminating Infusion Confusion
Eliminating Infusion Confusion (Drug Administrations in Non-facility Settings) Maryann C. Palmeter, CPC, CENTC Agenda Review of CPT codes (added in 2009) Documentation principles Key definitions What s
More informationLORNA E. T. STEARNE,* CLARISSA KOOI, WIL H. F. GOESSENS, IRMA A. J. M. BAKKER-WOUDENBERG, AND INGE C. GYSSENS
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2001, p. 243 251 Vol. 45, No. 1 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.1.243 251.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationPharmacokinetics of Cloxacillin in Humans
Pharmacokinetics of Cloxacillin in Humans Pages with reference to book, From 299 To 303 Tasneem Ahmad, S.M. Khursheed, Mohammad Aslam ( Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi,
More informationEVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS
EVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS Guideline Title Evaluation of the Safety of Veterinary Medicinal Products for the Target Animals Legislative Basis Directive
More informationMATERIALS AND METHODS
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1998, p. 2521 2526 Vol. 42, No. 10 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Interaction of Streptococcus
More informationPublished 13 June 2011 Page May 2011
filgrastim, 30 million units (300 micrograms)/0.5ml, 48 million units (480 micrograms)/0.5ml, solution for injection or infusion in pre-filled syringe (Zarzio ) SMC No. (704/11) Sandoz Ltd 06 May 2011
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationShionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S ), a Siderophore Cephalosporin
Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin Osaka, Japan, April 22, 2017 - Shionogi & Co., Ltd. today announced
More informationBeta-Lactam ELISA Kit
Beta-Lactam ELISA Kit Cat.No: DEIAKB2 Lot. No. (See product label) Size 96T Intended use The Beta-Lactam ELISA Test Kit is a competitive enzyme immunoassay for the quantitative analysis of beta-lactams
More informationVerification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
More information01/08/2018. Control of Microbial Growth. Methods. Terminology. Disinfectants and Antiseptics. Three approaches. Cleaning. Chemical.
Control of Microbial Growth Disinfectants and Antiseptics 1 Methods 2 Three approaches Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical elimination Cleaning Filtration
More informationPharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
More informationNIMBUS The Next Generation in Antimicrobial Protection. October, 2010
NIMBUS The Next Generation in Antimicrobial Protection October, 2010 What is NIMBUS? NIMBUS represents a breakthrough in antimicrobial technology for wound care and other medical device applications No
More informationANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy
ANTICOAGULANT THERAPY REVISITED 2004 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most
More informationAN EXAMINATION OF THE EFFECTS OF SIMVASTATIN ON INNATE IMMUNE RESPONSES TO S. AUREUS A RESEARCH PAPER BY TRACI STANKIEWICZ
AN EXAMINATION OF THE EFFECTS OF SIMVASTATIN ON INNATE IMMUNE RESPONSES TO S. AUREUS A RESEARCH PAPER BY TRACI STANKIEWICZ SUBMITTED TO THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIRMENTS SET
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Laparoscopic vs open nephrectomy in 210 consecutive patients: outcomes, cost, and changes in practice patterns Kercher K W, Heniford B T, Matthews B D, Smith T I, Lincourt A E, Hayes D H, Eskind L B, Irby
More informationKinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis
Journal of Antimicrobial Chemotherapy Advance Access published August 30, 2006 Journal of Antimicrobial Chemotherapy doi:1093/jac/dkl334 Kinetics of galactomannan in surgical patients receiving perioperative
More informationKey words: Paracetamol, antibacterial activity, chemical preservative, zone of inhibition.
In Vitro Assessment of Antibacterial Activity of lamatecara Preservatives Abstract: The objective of the current research was to evaluate the efficacy of different preservatives of paracetamol syrup against
More informationHuman pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
Journal of Antimicrobial Chemotherapy (2005) 55, Suppl. S2, ii25 ii30 doi:10.1093/jac/dki008 JAC Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
More informationReceived 26 April 2000/Returned for modification 21 October 2000/Accepted 26 December 2000
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 927 931 Vol. 45, No. 3 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.3.927 931.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationVoriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012
Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0 20 May 2012 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationGuideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products
1 2 3 4 24 September 2015 EMA/CHMP/594085/2015 Committee for Human Medicinal Products (CHMP) 5 6 7 8 Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal
More informationSYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study
More informationPharmacokinetic Profiles of Ceftazidime after Intravenous Administration in Patients Undergoing Automated Peritoneal Dialysis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2011, p. 2523 2527 Vol. 55, No. 6 0066-4804/11/$12.00 doi:10.1128/aac.01543-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Pharmacokinetic
More informationPopulation pharmacokinetics of tazobactam/ piperacillin in Japanese patients with community-acquired pneumonia
Aug. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 4 189 1 Population pharmacokinetics of tazobactam/ piperacillin in Japanese patients with community-acquired pneumonia YUKIHIRO HAMADA 1, *, SAKI TAKAHASHI
More informationGuidelines for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel
Guidelines for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes
More informationProtocols for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel
Protocols for Laboratory Verification of Performance of the FilmArray Blood Culture Identification (BCID) Panel Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes
More informationRecommendation: Agenda no. File no Name of firm Recommendations /14DC Rifampicin. Dr. P V Dave, Addl. Director, Health Services, (Guj.
Recommendation: The 15 th SEC (Antimicrobial, Anti-parasitic & Antifungal, Antiviral) deliberated the proposals on 08.12.2014 and recommended the following:- Agenda 1 12-51/14 Rifampicin 2 12-83/09- Ampucare
More informationReport on New Patented Drugs - Invanz
Report on New Patented Drugs - Invanz October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationThe Prato Polymyxin Consensus. Roger L Nation PhD Monash Institute of Pharmaceutical Sciences Monash University, Melbourne, Australia.
The Prato Polymyxin Consensus Roger L Nation PhD Monash Institute of Pharmaceutical Sciences Monash University, Melbourne, Australia 24 th ECCMID Barcelona, Spain 10-13 May 2014 1 st International Conference
More informationPharmacodynamics of Metronidazole Determined by a Time-Kill Assay for Trichomonas vaginalis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1995, p. 1848 1852 Vol. 39, No. 8 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Pharmacodynamics of Metronidazole Determined by a Time-Kill
More informationNEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS
MEDIA RELEASE FOR IMMEDIATE RELEASE 15 September 2014 NEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS A team from A*STAR s Institute of Chemical and
More informationAN TB IOTIC. This project is funded by the European Union. This project is funded by the European Union.
TUBERCULOSIS Tuberculosis () today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of patients has never been higher than today and the growing proportion of drug-resistant
More informationProtocols for Laboratory Verification of Performance of the BioFire FilmArray Blood Culture Identification (BCID) Panel
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Blood Culture Identification (BCID) Panel A Laboratory Protocol for Use with Live s Purpose The Clinical Laboratory Improvement
More informationIdentification of the In Vivo Pharmacokinetics and Pharmacodynamic Drivers of Iclaprim
AAC Accepted Manuscript Posted Online 29 January 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.02550-17 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 Identification of the
More informationOpen clinical trial: Plasma levels of artemether and dihydroartemisinin for two commercially available artemether intramuscular injections.
Open clinical trial: Plasma levels of artemether and dihydroartemisinin for two commercially available artemether intramuscular injections. Principal investigator: L. K. Penali. Abstract To 23 patients
More informationTest Method of Specified Requirements of Antibacterial Textiles for Medical Use FTTS-FA-002
Test Method of Specified Requirements of Antibacterial Textiles for Medical Use FTTS-FA-002 FTTS-FA-002 Antibacterial Textiles for Medical Use Antibacterial Textiles suppress and even kill harmful bacteria
More informationDisclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018
Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested
More informationDETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR. TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI
1299 DETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI Department of Microbiology, School of Medicine, Gunma University,
More informationHELICA BIOSYSTEMS, INC. HIGH SENSITIVITY HUMAN C-REACTIVE PROTEIN FOR RESEARCH USE ONLY (Not for in vitro diagnostic use)
INTENDED USE HELICA BIOSYSTEMS, INC. HIGH SENSITIVITY HUMAN C-REACTIVE PROTEIN FOR RESEARCH USE ONLY (Not for in vitro diagnostic use) The Helica C-reactive protein assay is intended for the detection
More informationPharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats
Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats M. Maillard 1, D. Mordasini,D 1. Spaggiari 2, O. Phan 1, M. Ivarsson 3, R. Maj 3, L.A. Décosterd
More informationSusceptibility Tests
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1982, p. 213-217 Vol. 16, No. 2 0095-1137/82/080213-05$02.00/0 In Vitro Studies with Cefotaxime: Disk Diffusion Susceptibility Tests SMITH SHADOMY* AND EDWARD L.
More informationBringing True Novelty to the Anti-Infective Space
Bringing True Novelty to the Anti-Infective Space New Class of Antibacterials Based on a Unique Mechanism of Action Dr Dawn Firmin SMi s 17 th Annual Conference on Superbugs & Superdrugs March 2015 1 Contents
More informationVIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS
VIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS Investigational Medicinal Products 1. Paragraph 8.1: The protocol states that all drugs will need to be provided from commercial stock. However,
More informationInt.J.Curr.Microbiol.App.Sci (2014) 3(10)
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 810-815 http://www.ijcmas.com Original Research Article Comparison of Tissue Culture plate method, Tube Method and Congo Red Agar Method for the detection
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationMeropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group
Journal of Antimicrobial Chemotherapy (99) 7, 599-606 Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group J. A. Garcia-Rodriguez, J. E. Garcia Sanchez,
More informationResult:COMPLETE Report Date: December 28 th, 2015
Send to: Clean Water Environmental, LLC 1939 Talamore Court Southeast, Grand Rapids, MI 49546 Dr. Dale Williams Result:COMPLETE Report Date: December 28 th, 2015 Customer Name: Clean Water Environmental,
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationCME/SAM. Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome?
Microbiology and Infectious Disease / Laboratory Detection of AmpC β-lactamase Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome? Kenneth H. Rand, MD, 1 Bradley Turner, MD,
More informationSession 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
More informationPrior Authorization Criteria Hemophilia/Blood Factor Products
Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness
More informationTransmission Electron Microscopic Study of Antibiotic Action on Klebsiella pneumoniae Biofilm
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2002, p. 2679 2683 Vol. 46, No. 8 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.8.2679 2683.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationUW Medicine Alternative Monitoring for Antithrombotic Agents
Tags: monitoring alternative monitoring SUMMARY OF ANTICOAGULATION LAB TESTS AT UWMedicine Description Order Code Specimen Collection Availability Turn-Around Time Anti Xa Based Tests antixa for heparin
More informationTurbidimetric Bioassay for Carbenicillin
ANTMWICGOBAL AGENTS AND CHEMOTHEAPY, Mar. 1973, p. 364-368 Vol. 3, No. 3 Copyright 1973 American Society for Microbiology Printed in U.S.A. Turbidimetric Bioassay for Carbenicillin JOSEPH P. STANKEWICH
More informationPostantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1998, p. 414 418 Vol. 42, No. 2 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Postantibiotic and Sub-MIC Effects of and against Staphylococcus
More informationChanges in the Pharmacokinetics of Ciprofloxacin and Fecal Flora During Administration of a 7-Day Course to Human Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1984, P. 757-761 0066-4804/84/110757-05$02.00/0 Copyright X3 1984, American Society for Microbiology Vol. 26, No. 5 Changes in the Pharmacokinetics of Ciprofloxacin
More informationGuideline for Bioequivalence Studies of Generic Products. December 22, 1997
Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products
More informationSelenium nanoparticles and their utilization in scaffolds. Prof. RNDr. Vojtech Adam, Ph.D. Mgr. Dagmar Hegerova, Ph.D. Mendel University in Brno
Selenium nanoparticles and their utilization in scaffolds Prof. RNDr. Vojtech Adam, Ph.D. Mgr. Dagmar Hegerova, Ph.D. Mendel University in Brno 2 Content 1. Nanoparticles silver, selenium Staphylococcus
More informationUse of Molecular Assays for Resistance Detection
Use of Molecular Assays for Resistance Detection Antimicrobial resistance and susceptibility are complex, and current in vitro methods have been developed to predict a microorganism s response to antibacterial
More information